Pancreatic Cancer Clinical Trials

Showing 61-80 of 896 trials

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

NCT06353646

This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with immunocheckpoint inhibitor and chemotherapy in pancreatic cancer patients following surgical resection.

Pancreatic Cancer

Wu Wenming28 participantsStarted Mar 2024

Beijing, Beijing Municipality, China

RECRUITINGPhase 1

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Amgen350 participantsStarted May 2024

Bakersfield, California, United States • Duarte, California, United States • Duarte, California, United States +74 more locations

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Related Searches

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma

A Study of MGC026 in Participants With Advanced Solid Tumors

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer